Attached files

file filename
EX-99.1 - EXHIBIT 99.1 - Sucampo Pharmaceuticals, Inc.a6855315ex99_1.htm

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549


FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 8, 2011

Sucampo Pharmaceuticals, Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware

001-33609

30-0520478

(State or Other Jurisdiction

of Incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

4520 East-West Highway, 3rd Floor

Bethesda, Maryland

20814

(Address of Principal Executive Offices) (Zip Code)


Registrant’s telephone number, including area code: (301) 961-3400

 
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Item 8.01.  Other Events.

On September 8, 2011, the registrant’s Board of Directors authorized the repurchase of up to an aggregate of $2 million of its Class A common stock out of the $10 million previously approved by the Board in December 2008.  The repurchase program is expected to continue through to the third quarter of 2012 unless extended or shortened.

Item 9.01 Financial Statements and Exhibits
 
(d) Exhibits
 
The following exhibit relating to Item 8.01 shall be deemed to be furnished, and not filed:
 
99.1 Press Release issued by the registrant on September 8, 2011.


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

SUCAMPO PHARMACEUTICALS, INC.

 

 
Date: September 8, 2011 By:

/s/  THOMAS J. KNAPP

 

Name:

Thomas J. Knapp

 

Title:

Sr. VP, General Counsel & Corporate Secretary


EXHIBIT INDEX

Exhibit No.

Description

 

99.1

Press release issued by the registrant on September 8, 2011